NKGen Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-82.95	-26.75	-23.27
Depreciation & Amortization	1.2	1.21	1.24
Stock-Based Compensation	4.14	0.07	0.09
Other Operating Activities	53.44	2.89	1.45
Change in Accounts Receivable	0.03	-0.03	0.11
Change in Accounts Payable	3.99	0.44	0.96
Change in Other Net Operating Assets	-1.8	-0.38	-0.14
Operating Cash Flow	-21.95	-22.56	-19.55
Capital Expenditures	-	-0.1	-0.4
Sale (Purchase) of Intangibles	-0.05	-0.06	-0.06
Investing Cash Flow	-0.05	-0.16	-0.46
Short-Term Debt Issued	10.29	23	20.5
Long-Term Debt Issued	16.22	-	-
Total Debt Issued	26.51	23	20.5
Short-Term Debt Repaid	-0.3	-0.68	-0.4
Total Debt Repaid	-0.3	-0.68	-0.4
Net Debt Issued (Repaid)	26.21	22.33	20.1
Issuance of Common Stock	1.68	0.16	0.06
Other Financing Activities	-5.73	-	-
Financing Cash Flow	22.16	22.49	20.16
Net Cash Flow	0.16	-0.23	0.15
Free Cash Flow	-21.95	-22.66	-19.95
Free Cash Flow Margin	-	-29425.97%	-4683.33%
Free Cash Flow Per Share	-1.42	-3.56	-1.40
Levered Free Cash Flow	11.32	-16.94	-
Unlevered Free Cash Flow	11.78	-15.5	-
Change in Net Working Capital	-25.08	1.4	-

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.